2curex CEO after IPO: ”It’s pretty crazy”

For the first time, 2curex’s shares have been traded on the Nasdaq First North in Stockholm and the IPO brings new opportunities to the Danish company that was founded in a basement 11 years ago.

Photo: Nasdaq

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Zealand Pharma indgår australsk samarbejde

Zealand Pharma har indgået et nyt samarbejde med et australsk selskab rettet mod udvikling af peptid-baserede lægemidler mod mavetarmlidelser – det danske biotekselskabs helt store fokusområde.

Related articles